Attachment 2
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
SYNERON MEDICAL Ltd. POLARIS LV

This summary of safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.

Submitter: Syneron Medical Ltd., Sultam Industrial park, P.O.B. 550, Yokneam Elite 20692, Israel.
Tel. +972-4-909-7424 ext. 7604, Fax +972-4-909-7417

Name of the Device: Polaris LV

Predicate Devices: The Polaris LV is substantially equivalent to a combination of the following devices: the Polaris DS, manufactured by Syneron Medical Ltd. and subject of K024064; the PhotoDerm Nd:YAG Accessory, manufactured by ESC Medical Ltd., and subject of K980537; the SLP 1000, manufactured by Palomar Medical Technologies Inc., and subject of K013028; the Dornier Medilas D SkinPulse Laser, manufactured by DornierMedTech, and subject of K020339.

Device Description: The Polaris LV is a device that is used for treatment of vascular lesions. The Polaris LV treatment is based on the principle of selective (electromagnetic) thermolysis. According to this principle, parameters of optical and RF energy (spectrum, exposure duration and energy density) are chosen and optimized to selectively damage vascular lesions without damaging the surrounding tissues.

The Polaris LV is intended for use in dermatology for treatment of vascular lesions.

Based upon an analysis of the overall performance characteristic for the device, Syneron Medical Ltd. believes that no significant differences exit. Therefore the Polaris DS should raise no new issues of safety or effectiveness.

Date Dr. Amir Waldman,
Director regulatory affairs
Syneron medical Ltd.
Amir Waldman, M.D.
Director, Regulatory Affairs
Syneron Medical Ltd.
Sultam Industrial Park
P.O.B. 550 Yokneam Elite
20692, Israel

Re: K030186
Trade/Device Name: Polaris LV
Regulation Number: 21 CFR 878.4810
Regulation Names: Laser surgical instrument for use in general and plastic surgery and in dermatology
Regulatory Class: II
Product Codes: GEX
Dated: January 17, 2003
Received: January 21, 2003

Dear Dr. Waldman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
510(k) Number (if known) **K030186**

Device Name **Polaris LV**

Indications For Use:

The Polaris LV is indicated for treatment of vascular lesions.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use **X** OR Over The Counter Use

(Per 21 CFR 801.109) (Optional Format 1-2-96)

(Division Sign-Off)  
Division of General and Neurological Devices

510(k) Number **K030186**